Alprazolam Tablets — Class II drug recall D-1013-2019
Terminated recall by Mylan Institutional, Inc. (d.b.a. UDL Laboratories), reported 2019-03-27, distributed nationwide. Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT s
| Recall number | D-1013-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Mylan Institutional, Inc. (d.b.a. UDL Laboratories), Rockford, IL, United States |
| Recall initiated | 2019-01-18 |
| Classified | 2019-03-20 |
| Reported by FDA | 2019-03-27 |
| Terminated | 2020-04-29 |
| Distributed | Nationwide (US) |
| Quantity | 10,281 ud |
| Reason classes | specification failure |
| NDC | 51079-0788-20 |
| Lot numbers | 3095198, 3096266, 3098776 |
| Expiration dates | 2019-05 |
Product
Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-788-20
Reason for recall
Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1013-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.